

Ref no: 032160919
From: Public
Date: 16/09/19
Subject: Hereditary angioedema

REQUEST

In the last 6 months, how many patients with Hereditary angioedema (HAE) have been treated with,
Berint
Cinryze
Firazyr
Ruconest
Takhzyro
Tranexamic acid
Other

RESPONSE

Less than 5 patients have had a diagnosis of Hereditary angioedema (HAE) during their stay. We are unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure. There is, therefore, no public interest test to apply.

As the drugs stated in your request are not coded, this would require a manual audit of patient records that would result in the trust exceeding the appropriate cost limit. Under section 12 of the Freedom of Information Act St Helens & Knowsley Teaching Hospitals Trust does not have to comply with a request if we estimate that the cost of complying with your request would exceed the appropriate limit of £450. The appropriate limit has been specified in regulations. This represents the estimated cost of one person spending 2½ working days in answering the remainder of your questions. As such, we are

unable to inform you which of the drugs in your request would have been used.